MDW - Medication Therapy Management (MTM)

The District of Columbia’s Health Care Finance Agency is forecasting a contract for Medication Therapy Management services, scheduled for release in 2026, to support comprehensive pharmaceutical care for residents. This initiative aims to optimize medication use, reduce adverse drug events, and improve health outcomes through personalized therapy reviews, patient education, and coordination with providers. The solicitation is anticipated to be open to qualified vendors capable of delivering MTM services across the district, though specific eligibility requirements, performance metrics, and submission guidelines have not yet been published. The contract will likely focus on serving Medicare Part D beneficiaries and other high-risk populations within the district’s public health system. There is currently no designated set-aside type, NAICS code, or specific office address provided, indicating the procurement is still in early planning phases. The point of contact information is absent, suggesting that interested parties should monitor the official procurement portal for updates as the solicitation nears release. The place of performance is expected to encompass all areas served by the District of Columbia’s healthcare programs, with services delivered both in-person and remotely to ensure broad accessibility. Stakeholders are encouraged to prepare by reviewing existing MTM frameworks and aligning capabilities with the district's health equity and cost-containment priorities.